Treatment with a DPP-4 inhibitor at time of hospital admission for COVID-19 is not associated with improved clinical outcomes: data from the COVID-PREDICT cohort study in The Netherlands

PURPOSE: Inhibition of dipeptidyl peptidase (DPP-)4 could reduce coronavirus disease 2019 (COVID-19) severity by reducing inflammation and enhancing tissue repair beyond glucose lowering. We aimed to assess this in a prospective cohort study. METHODS: We studied in 565 patients with type 2 diabetes...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Diabetes Metab Disord
Asıl Yazarlar: Meijer, Rick I., Hoekstra, Trynke, van den Oever, Niels C. Gritters, Simsek, Suat, van den Bergh, Joop P., Douma, Renée A., Reidinga, Auke C., Moeniralam, Hazra S., Dormans, Tom, Smits, Mark M.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Springer International Publishing 2021
Konular:
Research Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC8233181/
https://ncbi.nlm.nih.gov/pubmed/34222054
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40200-021-00833-z
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller